Linagliptina Zentiva

Linagliptin, the active ingredient in Linagliptina Zentiva, is a Dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is indicated for the management of blood glucose in adults with type 2 diabetes mellitus, helping to improve glycaemic control when combined with diet and exercise.

GNH USA supplies Linagliptina Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company emphasizes quality assurance, regulatory compliance, and reliable logistics for global distribution throughout.

Linagliptin is used to improve glycaemic control in the type 2 diabetes mellitus therapeutic pathway.

- Type 2 diabetes mellitus (monotherapy): reduces fasting and post‑prandial glucose levels, leading to lower HbA1c. - Type 2 diabetes mellitus (combination therapy): added to metformin or other oral agents to achieve additional glycaemic reduction. - Type 2 diabetes mellitus (adjunct to diet and exercise): supports lifestyle measures to maintain target blood glucose.

Linagliptina Zentiva may be associated with several adverse reactions, which are grouped by frequency.

Common Side Effects: - Upper respiratory tract infection - Nasopharyngitis - Headache - Dyspepsia

Serious or Rare Side Effects: - Pancreatitis - Severe hypersensitivity reactions (e.g., angioedema, anaphylaxis) - Bullous skin disorders - Hypoglycaemia (when combined with insulin or sulfonylureas)

Before prescribing Linagliptina Zentiva, clinicians should consider the following precautions.

- Renal impairment: dose adjustment is not required, but monitor renal function regularly. - Hepatic impairment: use with caution; monitor liver enzymes. - Elderly patients: monitor for hypoglycaemia when used with insulin or sulfonylureas. - Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk. - Drug interactions: review concomitant medications for potential DPP‑4 inhibitor interactions. - Store at ambient temperature: keep below 25 °C, in original packaging, protect from moisture and light.

Linagliptina Zentiva can interact with other medicines; awareness of the interaction level helps guide clinical decisions.

Major Interactions (Avoid): - Concomitant use with strong CYP3A4 inducers (e.g., rifampicin) may reduce linagliptin exposure. - Co‑administration with insulin or sulfonylureas increases risk of hypoglycaemia.

Moderate Interactions (Monitor Closely): - Combination with other DPP‑4 inhibitors is not recommended; additive effect may increase adverse events. - Use with diuretics may affect blood glucose monitoring; adjust dose as needed. - Concurrent use with drugs that affect renal excretion (e.g., probenecid) may alter linagliptin levels.